Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC 2022 | Toxicities associated with combining stereotactic ablative radiotherapy (SABR) and immunotherapy

Stephanie Kroeze • 7 Aug 2022
WCLC 2022
Lung Cancer Antibodies Ipilimumab Nivolumab

Stephanie Kroeze, MD, PhD, University Hospital of Zürich (Universitätsspital Zürich), Zurich, Switzerland, discusses the toxicities associated with combining stereotactic ablative radiotherapy (SABR) with immunotherapy. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.

More from Stephanie Kroeze

1:00
Combining SABR and immunotherapies for NSCLC
Stephanie Kroeze • 7 Aug 2022
0:28
Stereotactic ablative radiotherapy (SABR) for lung cancer treatment
Stephanie Kroeze • 7 Aug 2022

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals